[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539646":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":10,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":28,"acronym":10,"eligibilityCriteria":29,"healthyVolunteers":26,"sex":30,"minAge":31,"maxAge":32,"enrollmentInfo":33,"targetDuration":36,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"IMM patients with tumors",null,"Patients with IMM will be grouped according to the type of positive myositis-specifc autoantibody,and then again according to whether and what type of tumor they had comorbid.",[13],"Other: no interventions were involved",{"label":15,"type":10,"description":11,"interventionNames":16},"IMM patients without tumors",[13],[18],{"type":6,"name":19,"description":19,"armGroupLabels":20,"otherNames":10},"no interventions were involved",[9,15],{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Qiong Fu","Director","100539646",false,"NCT06306547","Clinical Study Cohort of Idiopathic Inflammatory Myositis","Inclusion Criteria:Subjects must meet the following criteria for inclusion in this study: meet the 2017 EULAR\u002FACR classification criteria for inflammatory myopathy (IIM) or the 2018 ENMC-DM classification criteria (see above), plus:\n\n1. Age≥ 18 years old and ≤ 75 years old\n2. Meet the 2017 EULAR\u002FACR classification criteria for inflammatory myopathy (IIM), the above score ≥ 5.5 points if there is no muscle biopsy, and 6.7 points ≥ if there is muscle biopsy\n3. Cooperate with follow-up, examination and treatment and voluntarily sign the informed consent form.\n\n   \\-\n\n   Exclusion Criteria:Potential subjects who meet the inclusion criteria will be excluded if they meet any of the following criteria:\n\n   a. IIM with other connective tissue diseases; b. Negative myositis antibody test; c. Those who are in the period of acute infection, or have a history of active tuberculosis in the past; d. People with allergies or allergies to multiple drugs; e. Those who have mental illness or other reasons and cannot cooperate with examination, follow-up or treatment; f. Women who are pregnant, or are trying to become pregnant; g. Those who are participating in or have participated in clinical trials within the specified time.\n\n   \\-","ALL","18 Years","75 Years",{"count":34,"type":35},1000,"ESTIMATED","3 Years","OBSERVATIONAL","Idiopathic inflammatory myositis (IIM), also known as myositis, are a heterogeneous group of diseases characterized by chronic inflammation of striated muscles and skin, with different clinical manifestations, treatment responses, and prognosis. This project will build a clinical follow-up cohort for idiopathic inflammatory myositis (IIM) centered on Renji Hospital, Shanghai Jiao Tong University School of Medicine, to promote the clinical and pathogenesis of this group of diseases.",[40],"Idiopathic Inflammatory Myopathies","NOT_YET_RECRUITING","2024-03-09",{"date":44,"type":45},"2024-03-12","ACTUAL",{"date":47,"type":35},"2024-04-01",{"date":49,"type":35},"2034-04-01",{"name":5,"class":6}]